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Abstract
Background: There is a significant association between effects of interferon-alpha treatment and the risk of developing
hyperglycemia in patients with chronic hepatitis C virus (HCV) infection. The objective of this systematic review and meta-
analysis on the basis of published observational studies was to estimate risk of hyperglycemia in chronic HCV patients who
had acquired sustained virological responses (SVR) compared to those without SVR.
Methodology: We identified eligible studies by searching the relevant databases, including PubMed, Embase, and Google,
for papers published between January 1990 and April 2011. The selection of eligible papers was carried out using a scoring
system based on guidelines and inclusion criteria that were established before the articles were identified. Heterogeneity
across studies was determined and the meta-analysis was performed following standard guidelines.
Conclusions: Eleven eligible studies provided data of the incidence of hyperglycemia in chronic hepatitis C patients with
SVR in comparison with patients without these conditions. The results demonstrated that SVR was associated with a lower
risk of hyperglycemia (odds ratio=0.497, 95% confidence interval 0.421–0.587, p,0.001), and there was no evidence of any
substantial between-study heterogeneity (I
2=24.4%, p.0.1). Results of meta-regression showed patients with different
baseline glucose (normal vs. abnormal) and patients with co-infected HIV (presence vs. absence) as the sources of low
heterogeneity (p,0.15).The lowest risk of hyperglycemia was described in patients with normal glucose baseline
(OR=0.402, 95%CI 0.297–0.543, p,0.001). This is the first systematic review and meta-analysis performed to examine the
association between SVR and risk of hyperglycemia in patients with HCV infection. Our meta-analysis suggests that SVR
reduce the risk of developing glucose abnormalities, especially in patients with normal glucose baseline.
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Introduction
Recent observational studies, demonstrate a significant asso-
ciation, but not causation, between effects of interferon-alpha
treatment (e.g., sustained virological response [SVR]) and the
risk of developing hyperglycemia in patients with chronic
hepatitis C virus (HCV) infection. Most of the existing reports
describe SVR reduce the incidence of hyperglycemia. However,
others reports are on the contrary. The objective of this
systematic review and meta-analysis on published observational
studies was to estimate risk of hyperglycemia in chronic HCV
patients who had acquired SVR compared to those without
SVR (NONSVR). The targeted population of this study was
defined as adults with HCV who were treated with interferon
(IFN)-alpha or PEG IFN-alpha monotherapy or plus ribavirin
(RBV) for 24 or 48 weeks and who were diagnosed as
hyperglycemia (i.e., diabetes and/or pre-diabetes).
Methods
Searching of the Relevant Databases
We conducted a search of the medical literature for articles
published between January 1990 and April 2011 using PubMed,
Embase, and Google. The mesh-terms or key words (‘hepatitis C’
OR ‘chronic hepatitis C’ OR ‘hepatitis c virus’) AND (‘glucose’
OR ‘glucose abnormalities’ OR ‘hyperglycemia’ OR ‘prediabetes’
OR ‘diabetes mellitus’ OR ‘insulin’ OR ‘insulin resistance’ OR
‘insulin deficiency’) AND (‘interferon alpha’ OR ‘peginterferon
alpha’ OR ‘interferon alfa’ OR ‘peginterferon alfa’ OR ‘IFN’)
were used to obtain the search string.
Selection
The meta-analysis was performed using summary data. No
restrictions were placed on sample size, or population. When
multiple reports were available for a single unique study
population, we included only the most recent or largest report.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39272Because bias in observational studies is a problem, we perform
the analysis (data permitting) to verify suspected sources of bias
and variability in the study findings [1,2].
Eligible studies met the following criteria. 1) They were
designed as cohort studies. 2) They involved chronic HCV
patients who were treated with IFN- alpha or PEG IFN-alpha
monotherapy or plus ribavirin for 24 or 48 weeks. 3) They
included expose (SVR) or unexposed (NONSVR) groups. 4) They
included data on the incidence rate of hyperglycemia.
Studies were excluded if they met any of following criteria: 1)
were not designed to discuss the key question; 2) were not
published as original articles (including letters, abstracts, reviews
and editorials); 3) were not published in English; 4) included
children, dialysis patients, pregnant women, or patients who had
undergone transplantation or been diagnosed with ketoacidosis,
diseases of the exocrine pancreas, any other endocrinopathies, or
cancer.
Validity Assessment
To determine the quality of each study, we created a scoring
system based on the guidelines developed by Moose [1], Quatso
[3], and Strobe [4]. We assessed five characteristics: 1) targeted
population as adults with chronic HCV (1 point if the diagnosis
was made by detecting either anti-HCV or HCV RNA [5]); 2)
clear definition of exposures (SVR) (1 point if SVR was defined as
the number of patients with detectable HCV RNA in serum by
sensitive testing within 24 weeks after the end of IFN-alpha
treatment); 3) clear definition of outcomes (incidence of hypergly-
cemia including diabetes and/or pre-diabetes) (1 point if diagnosis
of the normal glucose group, diabetes mellitus and pre-diabetes
was in accord with American Diabetes Association [ADA]
guidelines [6]); 4) study design (1 point if any justification was
given for the cohort and 1 point for appropriate inclusion and
exclusion criteria); and 5) statistical analysis (1 point was given if
adjustments were made for age, body mass index (BMI),family
history of type 2 diabetes, etc. as proven risk factors for the
development diabetes and pre-diabetes, and 1 point was given if
adjustments were made for SVR risk factors). Studies were graded
as ‘‘good quality’’ if they met at least six of seven points, and as
‘‘poor quality’’ if they met fewer than four points.
Data Abstraction
All of the eligible articles were reviewed by pairs of researchers;
each pair included at least one reviewer with clinical training and
one with training in epidemiology and research methods. One
reviewer completed the quality assessment and data-extraction
forms. Disagreements about eligibility were resolved by consensus.
The following information was extracted from each study included
in the current analysis: the number of patients with hyperglycemia
(diabetes and/or pre-diabetes), hazard ratio (HR) or odds ratio
(OR) estimating the association, study design, sample size, and
participant characteristics. Characteristics of patients, including
age, sex, cirrhosis, glucose baseline status, co-infected with human
immunodeficiency virus (HIV), ethnics, high BMI, family history
of diabetes, steatosis, homeostasis model assessment for insulin
resistance (HOMA-IR) values, ALT levels, HCV-RNA, HCV
genotype, liver fibrosis, naı ¨ve and experienced patients, types of
DM, alcohol consumption, and treatment schedules, were
recognized as confounding factors.
Quantitative Data Synthesis
Our primary goal was to assess the risk of hyperglycemia in
chronic HCV patients who had acquired SVR compared to those
without SVR. The relative risk was the ratio of the rate of the
index subjects to that of the control subjects. The OR was
generally a good estimate of the relative risk.
We used two models of meta-analysis (the random-effects model
and the fixed-effects model) to evaluate a summary estimate of the
overall association between SVR and hyperglycemia in adults with
chronic HCV. Heterogeneity was considered significant for p value
of Cochran’s Q statistic ,0.10 and I
2.50% [7,8]. I
2 was the
percentage of variation attributed to heterogeneity and was easily
interpreted. Higgins et al. tentatively suggested I
2 values between
25–50% be considered low, 50–75% be considered moderate, and
$75% be considered high. Our decision to perform fixed-effects
analysis or random-effects analysis was based on the results of the
heterogeneity assessments. As all tests showed great heterogeneity,
random effects models were preferred to pool the results. On the
contrary, fixed effects models were chosen.
Exploring the possible sources of heterogeneity between studies
was an important aspect of conducting a meta-analysis. Meta-
regression was applied to investigate the heterogeneity of the
studies [9]. According to the widely accepted minimum sample
size for regression analysis [10], we performed meta-regression
only when there were $10 comparable studies. Variables
significant at p,0.15 were considered potentially important
sources of between-study heterogeneity. A meta-regression was
performed involving confounding factors (i.e., baseline glucose, co-
infected HIV, cirrhosis, and treatment schedules), and study
characteristics (i.e., publication year, publication area, study
design, sample size, and quality score). We performed stratification
analyses according to baseline glucose (normal vs. abnormal),
presence vs. absence of cirrhosis, treatment schedules (PEG IFN-
alpha-2b/2a vs. IFN-alpha-2b/2a), publication area, and study
design.
A sensitivity analysis was performed by the sequential omission
of individual studies as a possible major source of heterogeneity.
Publication bias was investigated by Begg’s funnel plots and
Egger’s regression asymmetry test [11,12]. Funnel plot shapes did
not reveal obvious evidence of asymmetry, and all the p values of
Egger’s tests were more than 0.05, providing statistical evidence of
the funnel plots symmetry.
In this meta-analysis, if there was no event in one group, 0.5 was
added to each cell for these calculations [13].
Statistical analyses were conducted using STATA 12.0.
Results
Flow of Included Studies
The literature search identified 1096 English abstracts. After
reviewing the abstracts, 992 reports were excluded. Relevant full-
text publications (n=104) were identified for further detailed
evaluation, and 11 studies were identified as providing useful
information (1%). The most frequent reasons for exclusion
included: no relevant outcome reported (n=895); duplicates
(n=97); not designed to discuss the key question (n=77); not
considered an original publication or research (i.e., letters,
abstracts, reviews, editorials, etc.) (n=6); poor quality (n=10,
including studies containing data on patients that were not in
accordance with our diagnostic criteria (n=9); or the study was
not designed as a cohort study (n=1)). Therefore, two prospective
cohort studies and nine retrospective cohort studies were included
in our meta-analysis. We identified available data from two unique
studies in two publications [14,15] (Figure 1).
Study Characteristics
The main characteristics of these studies are described in
Table 1. They were all published between 2006–2010. The sample
SVR and Hyperglycemia
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studies were performed in Europe (n=6) and the others were
performed in Asia (n=5). Among these, nine studies were
performed in one hospital, and two studies were multicenter trials
(11 hospitals). Eight studies provided respective data on diabetes
mellitus (DM) or pre-diabetes [14–19] and other three studies
reported total data on DM and pre-diabetes [20–22].Only one
study [20] reported data in patients co-infected with HIV.
Table 2 shows a brief description of the patients included in the
meta-analysis. The mean patient age was 47.6 years (n=9),
ranging between 42.8–54.7years. The average BMI of these
studies was 24.2 kg/m
2 (n=9). The percentage of females was
37.22%, ranging between 15.6–38.7%. The proportions of
patients with normal glucose baseline were 40.34%. Of these
studies, two did not report the proportion of HCV genotype1
[15,21]. The prevalence rate of infection with genotype 1 was
72.55%, ranging between 37.5–100%. Of these studies, 10
reported data on the proportion of patients with cirrhosis
(17.14%). The mean alanine aminotransferase (ALT) of all
patients was 97.3 U/L(n=9), ranging between 69.73–114.36 U/
L. Only Asians (12.34%) were reported in these studies (n=4).
The proportions of patients administered IFN treatment was as
Figure 1. Flow of included studies. The reasons for exclusion included: no relevant outcome reported (n=895); duplicates (n=97); not designed
to discuss the key question (n=77); not considered an original publication or research (i.e., letters, abstracts, reviews, editorials, etc.) (n=6); poor
quality (n=10, including studies containing data on patients that were not in accordance with our diagnostic criteria (n=9); or the study was not
designed as a cohort study (n=1)). Therefore, two prospective cohort studies and nine retrospective cohort studies were included in our meta-
analysis.
doi:10.1371/journal.pone.0039272.g001
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IFN-a-2b/2a alone, and 60.96% were on Peg IFN-a-2a/2b.
Quantitative Data Synthesis
Eleven studies involving 3037 patients were included in the
meta-analysis. There was no evidence of substantial between-study
heterogeneity (I
2=24.4%, p.0.1); thus, the fixed-effects model
was used to pool the results. The results demonstrate that SVR is
associated with a lower risk of hyperglycemia in chronic HCV
patients (OR=0.497, 95% CI 0.421–0.587, p,0.001) (Figure 2).
It is well known that performing meta-regression in order to
explore sources of heterogeneity is appropriate, even if an initial
overall test for heterogeneity in insignificant [9,23]. Meta-
regression was applied to determine the heterogeneity of this
meta-analysis. Study characteristics and confounding factors were
investigated by univariate meta-regression (n$10). The study
including co-infected HIV patients [20] was significantly identified
as sources of heterogeneity (p,0.15). After excluding this study,
the incidence of hyperglycemia was 51.3% (OR=0.513, 95%CI
0.434–0.608, p,0.001) (I
2=1.1%, p.0.1). Among confounding
factors, baseline glucose was showed as the source of heterogeneity
(p,0.15).
Results in stratification analyses were as follows. The lowest risk
of hyperglycemia was described in patients with normal glucose
baseline (OR=0.402, 95%CI 0.297–0.543, p,0.001). And the
risk in patients with abnormal glucose before IFN-alpha treatment
was higher compared to those with normal glucose baseline
(OR=0.547, 95%CI 0.448–0.668, p,0.001). The highest risk was
reported in Asian (OR=0.597, 95%CI 0.385–0.925, p=0.02).
However, there was no significant difference between SVR and
NONSVR groups in Asian. In comparison with patients without
cirrhosis, cirrhosis patients had higher OR (0.528, 95%CI 0.440–
0.634, p,0.001). In retrospective studies, the incidence of
Table 1. Characteristics of meta-analysis eligible studies examining the association between SVR and Hyperglycemia.
Study Year Country Design
Hyper/
SVR
NOR/
SVR
Hyper/
NONSVR
NOR/
NONSVR Sample OR/HR
Simo, R. [16] 2006 Spain retrospective 14 82 47 91 234 HR0.489(0.278–0.890), p=0.018;
Lecube, A. [17] 2007 Spain retrospective 16 51 49 62 178 OR 2.72(1.12–6.59), p=0.026;
Giordanino, C. [18] 2008 Italy prospective 12 81 21 88 202 HR0.88(0.38–2.02), p=0.758;
Romero-Gomez,M.-1 [14] 2008 Spain retrospective 143 432 182 302 1059 OR 0.44(0.20–0.97), p=0.04;
Romero-Gomez,M.-2 [14] 2008 Spain prospective 50 382 74 228 734 NR
Cesari, M. [20] 2009 Italy retrospective 7 44 21 24 96 OR0.133(0.034–0.512), p=0.003;
Chehadeh, W. [21] 2009 Kuwait retrospective 34 48 36 41 159 OR 8.50(7.1–14.6), p,0.001
Kawaguchi, Y.-1 [15] 2009 Japan retrospective 14 34 10 14 72 p=0.335;
Kawaguchi, Y.-2 [15] 2009 Japan retrospective 5 40 7 13 55 NR
Konishi, I. [19] 2009 Japan retrospective 30 62 42 64 197 NR
Mizuta, T. [22] 2010 Japan retrospective 6 17 11 17 51 p=0.38;
Hyper/SVR: the risk of hyperglycemia in CHC patients who acquired sustained virological responses; NOR/SVR: data of normal glucose in CHC patients who acquired
sustained virological responses; Hyper/NONSVR: the risk of hyperglycemia in CHC patients who did not acquire sustained virological responses; NOR/NONSVR: data of
normal glucose in CHC patients who did not acquire sustained virological responses; OR: odds ratio; HR: hazard ratio; NR: not reported.
doi:10.1371/journal.pone.0039272.t001
Table 2. Characteristics of patients in the meta-analysis.
Characteristics Number of patients Percent of patients
Age (means 47.6 years) 2823 92.95%(2823/3037)
BMI (means 24.2 kg/m
2) 2823 92.95%(2823/3037)
Female 1110 37.22%(1110/2982)
Genotype1 2048 72.55%(2048/2823)
With normal glucose baseline 1225 40.34%(1225/3037)
With HIV 96 3.16%(96/3037)
With cirrhosis 490 17.14%(490/2859)
With retreatment 105 23.23%(105/452)
With DM treatment 12 0.47%(12/2542)
ALT (means 97.3U/L) 2780 91.54%(2780/3037)
IFN-alpha 22b/2a+RBV treatment 604 25.55%(604/2364)
IFN-alpha 22b/2a alone 216 9.14%(216/2364)
PEG IFN-alpha 22b/2a+RBV 1441 60.96%(1441/2364)
BMI: body mass index; HIV: human immunodeficiency virus; DM: diabetes mellitus; ALT: alanine aminotransferase; IFN: interferon; RBV: ribavirin.
doi:10.1371/journal.pone.0039272.t002
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(I
2=31.3%, p.0.1).
Sensitivity and Publication Bias
Sensitivity analysis was performed by sequential omission of
individual studies. For analyses that included more than three
pooled individual studies, the significance of the OR was not
significantly altered by omitting any single study (data not shown).
Among 11 studies that estimated the association between SVR
and the incidence of hyperglycemia, no evidence of publication
bias was found in the main analysis (p.0.05) (Figure 3).
Study Quality
Ten studies (90.9%) were identified as good quality (i.e. $6
points). Six were missing a point for statistical analysis (6 points).
Four studies met all of the criteria of the quality- assessment tool,
and some adjustments were made for potential confounding
factors, such as age, BMI, family history of diabetes, HOMA-IR,
HCV genotype, HCVRNA levels, AST, ALT, and cirrhosis.
Discussion
To the best of our knowledge, this is the first systematic review
and meta-analysis performed to examine the association between
SVR and risk of hyperglycemia (DM and/or pre-diabetes) in
patients with HCV infection on the basis of published observa-
tional studies. Our meta-analysis, which was carried out on eligible
studies, suggests that SVR reduce the risk of developing glucose
abnormalities. Accordingly, NONSVR patients are at an almost
two-fold greater risk of developing glucose abnormalities com-
pared with SVR patients.
We found no significant evidence of statistical heterogeneity in
this meta-analysis. However, non-significant statistical heteroge-
neity could not be interpreted as evidence of homogeneity of
results of all included studies [24]. It is because tests of
heterogeneity have low power and might fail to detect as
statistically significant even a moderate degree of genuine
heterogeneity [25]. There was the low degree of statistical
heterogeneity in our meta-analysis (I
2,50%). The existence of
clinical or methodological heterogeneity would be expected to lead
to at least some degree of statistical heterogeneity in the results.
However, it must be ascertained that there are not substantial
clinical heterogeneity of all included studies and it is appropriate to
pool them prior to analysis. When combining observational
studies, some heterogeneity of design, populations, and outcome is
not avoided [1]. In this review, the participants were defined as
adults with HCV who were treated with IFN-alpha or PEG IFN-
alpha treatment and who were diagnosed as hyperglycemia. Other
Figure 2. ORs and 95% CI of the association between SVR and hyperglycemia. SVR was associated with a lower risk of hyperglycemia in
chronic HCV patients (OR=0.497; 95% CI 0.421–0.587). There was no evidence of substantial between-study heterogeneity.
doi:10.1371/journal.pone.0039272.g002
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status, co-infected HIV, ethnics, high BMI, family history of
diabetes, steatosis, HOMA-IR values, ALT levels, HCV-RNA,
HCV genotype, liver fibrosis, naı ¨ve and experienced patients,
types of DM, alcohol consumption, and treatment schedules) were
recognized as confounding factors caused by the selection bias.
However, the original studies do not provide enough data related
to these factors. Our proper attention was given to factors, such as
baseline glucose, co-infected with HIV, cirrhosis, and treatment
schedules.
Meta-analyses of observational studies, these are recognized as
non-randomized studies [2], present particular challenges because
of inherent biases. Ozminkowski RJ, et al. addressed selection bias
by aggregating the results of eligible studies according to birth
weight in the meta-analysis of 19 non-randomized studies and
found selection bias (infants at these birth weights) was a major
factor in the explanation of the significant heterogeneity [26].
Similarly, we collected and analyzed data of outcomes of included
studies according to baseline glucose, cirrhosis, co-infected HIV,
and treatment schedules. Results of meta-regression showed
patients with different baseline glucose (normal vs. abnormal)
and patients with co-infected HIV (presence vs. absence) as the
sources of heterogeneity (p,0.15). There was selection bias in this
meta-analysis. ‘Adjusted’ estimates were accomplished through the
use of stratification analysis. SVR was associated with a lower risk
of hyperglycemia in chronic HCV patients, especially in patients
with normal glucose baseline. Results in patients without infected
HIV showed that the OR was not significantly altered.
Other confounding factors might be potential sources of
heterogeneity. Unfortunately, we could not get enough data to
analysis and provided evidences for them. Simo, et al. [16]
demonstrated that after adjusting for the recognized predictors of
both type 2 diabetes and SVR (e.g., age, BMI, AST, ALT, fibrosis,
genotype, and duration of treatment), the OR for hyperglycemia
in patients with SVR is 0.48(95% CI 0.24–0.98, p=0.04)
compared with NONSVR patients. The results of our meta-
analysis do not contradict these findings. However, Giordanino,
et al. [18] showed the incidence of DM and pre-diabetes was not
significantly different between SVR and NONSVR patients after
adjusting for baseline risk factors of DM and the predictors of
a poor response. In such situations, these risk factors can be
considered only as hypotheses for evaluation in future studies.
We found no evidence of publication bias, as the result in
statistical analyses. There were no restrictions placed on sample
size, and population in our meta-analysis. Considering selected
published studies based on original articles and language
restrictions, we could not ignore publication bias.
Publication bias clearly is a major threat to the validity of any
type of review. Obviously, including data from unpublished studies
appears to be one way of avoiding this problem. However, the
inclusion of data from unpublished studies can itself introduce
bias. Unpublished studies may be of lower methodological quality
than published studies [27,28]. We also exclude studies published
in abstract form as following reasons. First, only about half are
published as a full manuscript [29,30]. Many abstracts are
recognizes as grey literatures and might be of lower quality [31].
Their inclusion will compromise the validity of a meta-analysis.
Second, abstracts could not provide enough information. This
could again bias the findings. If enough information of patients in
abstracts cannot be obtained, the search may be futile. Third,
abstracts do not escape publication bias [31]. Abstracts with
positive results tend to be accepted more frequently than those
with negative findings at conferences.
Our meta-analysis was based on studies published in English.
Language bias could be introduced. The effects of language bias
might be diminished recently because of more and more studies
published in international English-language journals [32].
There are some possible limitations to our meta-analyses. First,
the number of eligible studies is small. It leads to a lack of data on
some confounding factors that may influence the accuracy of the
results. Second, there is potential bias in the meta-analysis of
observational studies. Despite these limitations, our meta-analysis
suggests that SVR be associated with a low incidence of
hyperglycemia, especially in patients with normal glucose baseline.
Figure 3. Funnel plot. The funnel plot’s shape is in asymmetrical. There was no significant publication bias indicated in the main analysis.
doi:10.1371/journal.pone.0039272.g003
SVR and Hyperglycemia
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factors of hyperglycemia and SVR are needed to provide the
evidence of a possible association.
In conclusion, SVR reduce the risk of developing glucose
abnormalities, especially in patients with normal glucose baseline.
The results suggest that abnormal baseline glucose as the
significant risk factor and it is important to screen glucose levels
in patients before IFN-alpha treatment.
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